Patient Characteristics at Time of First PRRT Dose, n = 52
| Characteristic | Data |
|---|---|
| Women | 24 (46) |
| Age (y) | 70 (47–89) |
| NET primary location | |
| Ileum | 38 (73) |
| Jejunum | 6 (12) |
| Not available | 8 (15) |
| WHO classification | |
| NET-G1 | 25 (48) |
| NET-G2 | 22 (42) |
| Unknown | 5 (10) |
| Ki-67 (%) in 44 patients | 2.5 (1–16) |
| Non-MM metastatic sites | |
| 0 | 3 (5) |
| 1 | 17 (33) |
| 2 | 16 (31) |
| >2 | 16 (31) |
| Location of metastatic sites | |
| Liver | 45 (87) |
| Distant lymph node | 19 (37) |
| Peritoneum | 17 (33) |
| Bone | 14 (27) |
| Other* | 8 (15) |
| Treatment received before PRRT | |
| Primary tumor resection | 24 (46) |
| Liver surgery | 5 (10) |
| Liver embolization | 16 (31) |
| Somatostatin analogs | 47 (90) |
| Targeted therapy with everolimus | 10 (19) |
| Chemotherapy | 8 (15) |
| ECOG performance status | |
| 0–1 | 50 (96) |
| ≥2 | 2 (4) |
| Clinical CS | 39 (75) |
| Carcinoid heart disease | 7 (13) |
| MM-related symptoms | |
| No symptoms on MM | 26 (50) |
| Abdominal pain | 20 (38) |
| Diarrhea | 14 (27) |
| Occlusive syndrome | 8 (15) |
| Mesenteric ischemia symptoms | 5 (10) |
| Constipation | 3 (6) |
| Vomiting | 1 (2) |
| MM uptake on SRI | |
| Krenning 2 or equivalent for PET | 1 (2) |
| Krenning 3 or equivalent for PET | 4 (8) |
| Krenning 4 or equivalent for PET | 47 (90) |
| CgA > 2 ULN | 15 (29) |
| MM RECIST progression before PRRT | 20 (38) |
↵* Other metastatic sites were ovary (n = 3), pancreas (n = 1), breast (n = 1), lung (n = 1), pericardium (n = 2), testis (n = 1), and muscle (n = 1).
WHO = World Health Organization; ECOG = Eastern Cooperative Oncology Group; SRI = somatostatin receptor imaging; ULN = upper limit of normal.
Categoric data are number and percentage; continuous data are median and range.